| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 12 | 2023 | 913 | 1.220 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 253 | 1.050 |
Why?
|
| Myocardial Infarction | 11 | 2018 | 916 | 1.030 |
Why?
|
| Wounds and Injuries | 2 | 2025 | 246 | 0.870 |
Why?
|
| Accidental Falls | 1 | 2025 | 127 | 0.840 |
Why?
|
| Heart-Assist Devices | 3 | 2020 | 144 | 0.720 |
Why?
|
| Platelet Activation | 2 | 2014 | 27 | 0.710 |
Why?
|
| Quality Improvement | 3 | 2015 | 443 | 0.640 |
Why?
|
| Emergency Service, Hospital | 5 | 2025 | 1101 | 0.600 |
Why?
|
| Emergency Medicine | 1 | 2020 | 189 | 0.550 |
Why?
|
| Emergency Medical Services | 4 | 2019 | 266 | 0.500 |
Why?
|
| Medical Errors | 2 | 2015 | 196 | 0.490 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 255 | 0.490 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 131 | 0.470 |
Why?
|
| Patient Safety | 2 | 2015 | 242 | 0.470 |
Why?
|
| Hospitalization | 7 | 2025 | 1364 | 0.430 |
Why?
|
| Photoplethysmography | 4 | 2018 | 35 | 0.420 |
Why?
|
| Cost Savings | 1 | 2013 | 54 | 0.390 |
Why?
|
| Ischemic Preconditioning, Myocardial | 4 | 2007 | 23 | 0.380 |
Why?
|
| Clinical Protocols | 1 | 2013 | 134 | 0.370 |
Why?
|
| Retrospective Studies | 12 | 2025 | 6659 | 0.330 |
Why?
|
| Male | 30 | 2025 | 29893 | 0.320 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 173 | 0.320 |
Why?
|
| Massachusetts | 14 | 2018 | 2075 | 0.310 |
Why?
|
| Transportation of Patients | 1 | 2010 | 47 | 0.310 |
Why?
|
| Myocardial Reperfusion | 2 | 2008 | 24 | 0.310 |
Why?
|
| Myocardium | 3 | 2008 | 279 | 0.310 |
Why?
|
| Humans | 41 | 2025 | 63449 | 0.300 |
Why?
|
| Hospital Mortality | 8 | 2018 | 877 | 0.300 |
Why?
|
| Female | 29 | 2025 | 32883 | 0.300 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 480 | 0.290 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 5463 | 0.290 |
Why?
|
| Aged | 20 | 2025 | 14449 | 0.290 |
Why?
|
| Electrocardiography | 5 | 2023 | 554 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 45 | 0.270 |
Why?
|
| Time Factors | 10 | 2018 | 3768 | 0.270 |
Why?
|
| Tachycardia, Ventricular | 2 | 2018 | 129 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 42 | 0.240 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 168 | 0.240 |
Why?
|
| Heart Rate | 3 | 2016 | 322 | 0.240 |
Why?
|
| Algorithms | 5 | 2019 | 1003 | 0.240 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2005 | 28 | 0.230 |
Why?
|
| Pharmacists | 2 | 2023 | 127 | 0.220 |
Why?
|
| Middle Aged | 17 | 2018 | 17615 | 0.220 |
Why?
|
| Acute Disease | 6 | 2015 | 671 | 0.200 |
Why?
|
| Stroke Volume | 2 | 2015 | 329 | 0.200 |
Why?
|
| Support Vector Machine | 2 | 2023 | 23 | 0.190 |
Why?
|
| Inpatients | 2 | 2016 | 305 | 0.190 |
Why?
|
| Myocardial Ischemia | 3 | 2012 | 117 | 0.190 |
Why?
|
| Wearable Electronic Devices | 1 | 2023 | 69 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1308 | 0.190 |
Why?
|
| Emergencies | 2 | 2019 | 121 | 0.190 |
Why?
|
| Air Ambulances | 2 | 2014 | 31 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2023 | 495 | 0.180 |
Why?
|
| Consensus | 2 | 2020 | 208 | 0.180 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2018 | 32 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2025 | 406 | 0.180 |
Why?
|
| Prognosis | 9 | 2018 | 1749 | 0.180 |
Why?
|
| Communication | 2 | 2018 | 572 | 0.170 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2018 | 90 | 0.170 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 32 | 0.150 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2016 | 97 | 0.150 |
Why?
|
| Emergency Treatment | 1 | 2019 | 57 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2015 | 143 | 0.150 |
Why?
|
| Patient Discharge | 4 | 2020 | 512 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 174 | 0.140 |
Why?
|
| Hypovolemia | 1 | 2018 | 17 | 0.140 |
Why?
|
| Information Seeking Behavior | 1 | 2018 | 38 | 0.140 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 10 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 149 | 0.140 |
Why?
|
| Blood Volume | 1 | 2018 | 41 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2018 | 104 | 0.140 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 106 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 153 | 0.130 |
Why?
|
| Atrial Fibrillation | 2 | 2016 | 834 | 0.130 |
Why?
|
| Artifacts | 2 | 2016 | 125 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 1644 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 192 | 0.130 |
Why?
|
| Patient Admission | 1 | 2018 | 198 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2015 | 150 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2018 | 267 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 475 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2018 | 284 | 0.120 |
Why?
|
| Pulse | 1 | 2015 | 16 | 0.120 |
Why?
|
| Atrial Premature Complexes | 1 | 2015 | 13 | 0.120 |
Why?
|
| Radio Frequency Identification Device | 1 | 2015 | 11 | 0.120 |
Why?
|
| Telemetry | 1 | 2015 | 19 | 0.120 |
Why?
|
| Ventricular Premature Complexes | 1 | 2015 | 21 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2023 | 361 | 0.120 |
Why?
|
| Smartphone | 1 | 2015 | 69 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2015 | 3293 | 0.110 |
Why?
|
| Internet | 1 | 2018 | 469 | 0.110 |
Why?
|
| Peer Review, Health Care | 1 | 2014 | 17 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2014 | 50 | 0.110 |
Why?
|
| Lactates | 1 | 2014 | 29 | 0.110 |
Why?
|
| Survival Rate | 5 | 2015 | 851 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2015 | 203 | 0.110 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 119 | 0.110 |
Why?
|
| Executive Function | 1 | 2014 | 65 | 0.110 |
Why?
|
| Mobile Applications | 1 | 2015 | 136 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 76 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 65 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 136 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2014 | 106 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 158 | 0.100 |
Why?
|
| Risk Factors | 7 | 2018 | 5354 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2014 | 217 | 0.100 |
Why?
|
| Troponin I | 1 | 2012 | 35 | 0.090 |
Why?
|
| Rabbits | 4 | 2005 | 333 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 112 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 226 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 216 | 0.090 |
Why?
|
| Ambulances | 1 | 2012 | 24 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2012 | 166 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2016 | 429 | 0.090 |
Why?
|
| Transcription Factor AP-1 | 2 | 2001 | 41 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2014 | 568 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 873 | 0.090 |
Why?
|
| Biomarkers | 3 | 2018 | 1408 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 166 | 0.090 |
Why?
|
| Mortality | 1 | 2012 | 160 | 0.090 |
Why?
|
| Creatine Kinase | 2 | 2010 | 41 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2014 | 2570 | 0.090 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 29 | 0.080 |
Why?
|
| Critical Illness | 1 | 2014 | 321 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 39 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 23 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2014 | 1008 | 0.080 |
Why?
|
| Organizational Policy | 1 | 2010 | 52 | 0.080 |
Why?
|
| Adult | 7 | 2020 | 16826 | 0.080 |
Why?
|
| Medical Audit | 1 | 2010 | 65 | 0.080 |
Why?
|
| Incidence | 3 | 2018 | 1377 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 1147 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 540 | 0.070 |
Why?
|
| Platelet Function Tests | 1 | 2008 | 11 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 698 | 0.070 |
Why?
|
| Heart Conduction System | 1 | 2007 | 53 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 226 | 0.060 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2005 | 27 | 0.060 |
Why?
|
| Gap Junctions | 1 | 2005 | 17 | 0.060 |
Why?
|
| Comorbidity | 3 | 2015 | 1120 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2005 | 103 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 171 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 1173 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2005 | 96 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 147 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 58 | 0.050 |
Why?
|
| Apnea | 1 | 2004 | 32 | 0.050 |
Why?
|
| Age Factors | 3 | 2014 | 1558 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1119 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 2459 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2001 | 325 | 0.050 |
Why?
|
| Medication Errors | 1 | 2023 | 109 | 0.050 |
Why?
|
| Jejunum | 1 | 2002 | 14 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2002 | 16 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2023 | 369 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 1276 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 745 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2002 | 58 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1094 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 311 | 0.040 |
Why?
|
| Prevalence | 2 | 2016 | 1380 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2016 | 768 | 0.040 |
Why?
|
| Hypotonic Solutions | 1 | 2000 | 8 | 0.040 |
Why?
|
| Ischemia | 1 | 2002 | 205 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 259 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 178 | 0.040 |
Why?
|
| Animals | 7 | 2008 | 20663 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2015 | 5680 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2019 | 52 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 90 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 217 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 98 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 297 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 126 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 937 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2019 | 229 | 0.040 |
Why?
|
| Georgia | 1 | 2018 | 88 | 0.040 |
Why?
|
| Consumer Health Information | 1 | 2018 | 37 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 867 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2012 | 231 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2019 | 170 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 612 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2018 | 289 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2018 | 484 | 0.030 |
Why?
|
| Attitude to Computers | 1 | 2015 | 21 | 0.030 |
Why?
|
| Gelatin | 1 | 2015 | 30 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 53 | 0.030 |
Why?
|
| Movement | 1 | 2016 | 156 | 0.030 |
Why?
|
| Liver | 1 | 2000 | 855 | 0.030 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2014 | 13 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 419 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 78 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 367 | 0.030 |
Why?
|
| Motion | 1 | 2014 | 59 | 0.030 |
Why?
|
| Oximetry | 1 | 2014 | 48 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 154 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 173 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 25 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 142 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 163 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 221 | 0.030 |
Why?
|
| Naloxone | 2 | 2004 | 60 | 0.020 |
Why?
|
| Aspirin | 1 | 2014 | 171 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 978 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 392 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 433 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 65 | 0.020 |
Why?
|
| United States | 2 | 2019 | 7843 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 99 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 298 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 197 | 0.020 |
Why?
|
| Osmotic Pressure | 2 | 2001 | 16 | 0.020 |
Why?
|
| Narcotic Antagonists | 2 | 2004 | 136 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2013 | 219 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 331 | 0.020 |
Why?
|
| Heart | 2 | 2004 | 283 | 0.020 |
Why?
|
| Depression | 1 | 2018 | 894 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2079 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2001 | 3035 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 338 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 490 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1654 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 583 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2001 | 126 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 457 | 0.020 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 209 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2001 | 207 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 812 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 24 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 978 | 0.020 |
Why?
|
| Diuretics | 1 | 2009 | 59 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2010 | 156 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2009 | 104 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2001 | 936 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1256 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 465 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 199 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2681 | 0.020 |
Why?
|
| Life Style | 1 | 2009 | 311 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2008 | 124 | 0.020 |
Why?
|
| Rats | 2 | 2001 | 1980 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 374 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4695 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2008 | 261 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2005 | 40 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 1207 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1553 | 0.010 |
Why?
|
| Glyburide | 1 | 2002 | 9 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 2002 | 11 | 0.010 |
Why?
|
| Mesentery | 1 | 2002 | 15 | 0.010 |
Why?
|
| Potassium Channel Blockers | 1 | 2002 | 27 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 12 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2001 | 18 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2001 | 13 | 0.010 |
Why?
|
| Chromones | 1 | 2001 | 19 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2001 | 16 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 2001 | 27 | 0.010 |
Why?
|
| Culture Media | 1 | 2001 | 79 | 0.010 |
Why?
|
| Morpholines | 1 | 2001 | 89 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 202 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2001 | 139 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 3396 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 446 | 0.010 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2000 | 18 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 450 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2000 | 83 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 149 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 373 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 618 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 615 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2000 | 469 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2001 | 629 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 1552 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 10845 | 0.010 |
Why?
|